Galarubicin

Drug Profile

Galarubicin

Alternative Names: DA 125

Latest Information Update: 08 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A Pharmaceutical; Dong-A ST
  • Class Anthracyclines; Antineoplastics; Doxorubicins
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer metastases; Leukaemia; Non-small cell lung cancer

Most Recent Events

  • 17 Jan 2006 A preclinical study has been added to the Cancer pharmacodynamics section
  • 05 Apr 2004 Phase-II clinical trials in Leukaemia in South Korea (IV)
  • 05 Apr 2004 Preclinical trials in Cancer metastases in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top